H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company’s shares opened today at $13.20.
According to TipRanks, Arce is a 4-star analyst with an average return of 8.4% and a 38.20% success rate. Arce covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Mirum Pharmaceuticals, and Inventiva.
Currently, the analyst consensus on Assembly Biosciences is a Moderate Buy with an average price target of $36.00.
Based on Assembly Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $14.42 million. In comparison, last year the company had a GAAP net loss of $23.15 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ASMB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Assembly Biosciences (ASMB) Company Description:
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
